COVID vaccines
Japan approves Novavax COVID vaccine, adding fourth option
Jab, different from Pfizer and Moderna's mRNA vaccines, provides 'diversity'
Jab, different from Pfizer and Moderna's mRNA vaccines, provides 'diversity'
Aging population sparks need for services but cost pressures limit profitability
Failure to strike gold with Aduhelm prompts renewed focus on successor
Mixed variant has traits of delta and omicron, but details still scarce
2Q profit plunges 97% as selling prices decline for medical-grade products
Mobility startup LifeHub raises more than $800,000 in seed funding
Majority of growth investment set aside for these segments for 1st time
Underserved by mainstream health care, women from India to Japan turn to technology
Research group urges tighter rein on hospitals and speedier drug authorization
Overseas sales boom as omicron rages, but pandemic's end will clip windfall
Chinese leader calls for 'all necessary measures' to stop city's worst outbreak
Concerns over supply emerge as nations race to secure drugs for their people
People in risk areas shall not leave the capital, city spokesperson says
Malaysia's IHH, Indonesia's Siloam see big opportunities in VR, other tech
Hospital chain looks to M&As as Asia's aging population fuels health care demand
Korea Economic Daily said Alzheimer's drug creator possibly worth $42bn
Chinese education companies are biggest losers; Alibaba and Tencent tumble
Regular and repeated testing crucial, but not blanket shutdowns, Robert Redfield argues
Government promises to share Turkovac, but some question hurried approval process
Ministry needs more data after inconsistent findings, despite U.S. approval
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.